Cancer News and Research

Latest Cancer News and Research

Vaccine against H. pylori infection is within reach

Researchers from the University of Rhode Island are championing a recent breakthrough in the laboratory with hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and to therapeutics for inflammatory diseases.

23 Apr 2014

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

The Hematology/Oncology Pharmacy Association (HOPA) announced the recipients of the 2014 HOPA Membership Awards at its 10th Annual Conference in March. HOPA Membership Awards recognize members who have shown outstanding achievement in their field.

23 Apr 2014

Novartis to buy Glaxosmithkline's oncology unit

The deal, worth billions, will also see Novartis sell its vaccines unit to Glaxo and partner with Glaxo on their consumer divisions. Novartis also said it will sell its animal health division to Eli Lily.

23 Apr 2014

Anxiety experienced with false-positive mammogram does not negatively impact woman's well-being

Dartmouth researchers have found that the anxiety experienced with a false-positive mammogram is temporary and does not negatively impact a woman's overall well-being. Their findings are reported in "Consequences of False-Positive Screening Mammograms," which was published online in the April 21, 2014 JAMA Internal Medicine.

23 Apr 2014

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure.

23 Apr 2014

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. T

23 Apr 2014

Spire Leeds Hospital invests £200,000 in PENTAX Medical’s HD+ endoscopes

Spire Leeds Hospital has invested almost £200,000 in state-of-the-art endoscopy equipment from PENTAX Medical – which will benefit local patients. The extraordinarily high resolution images that the new equipment provides will help enhance the hospital’s detection of diseases, such as cancer, and enable earlier treatment which can improve patient outcomes.

From PENTAX Medical Company 23 Apr 2014

New computational tool identifies undiagnosed illnesses and unknown gene mutations

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

IMPAKT breast cancer conference abstracts online

Xenografts and mathematical modelling; liquid biopsy; nanotechnology; next generation genomics- Science is running fast and the impact of new technologies in the care of patients with breast cancer will be at the core of the sixth edition of the IMPAKT conference on translational research in breast cancer.

22 Apr 2014

University of Utah software successfully identifies diseases with unknown gene mutations in three separate cases

A computational tool developed at the University of Utah (U of U) has successfully identified diseases with unknown gene mutations in three separate cases, U of U researchers and their colleagues report in a new study in The American Journal of Human Genetics. The software, Phevor (Phenotype Driven Variant Ontological Re-ranking tool), identifies undiagnosed illnesses and unknown gene mutations by analyzing the exomes, or areas of DNA where proteins that code for genes are made, in individual patients and small families.

22 Apr 2014

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Treating patients with nonmetastatic clear-cell renal cell carcinoma with the tyrosine kinase inhibitor axitinib could not only prevent disease progression, but also shrink tumours before surgery, show the results of a phase II trial.

22 Apr 2014

Surgery promising for non-metastatic RCC with thrombus

Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology.

22 Apr 2014

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.

22 Apr 2014

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.

22 Apr 2014

Intravesical prostatic protrusion predicts post-surgery incontinence

The length of intravesical prostatic protrusion in men undergoing radical prostatectomy predicts the likelihood that they will develop incontinence following surgery, Korean researchers have shown.

22 Apr 2014

Nocturnal incontinence poses major burden after female bladder reconstruction

Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research.

22 Apr 2014

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.

22 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

First Edition: April 22, 2014

Today's early morning highlights from the major news organizations, including marketplace news about the Novartis purchase of GlaxoSmithKline's oncology unit for $14.5 billion.

22 Apr 2014

Cancer News and Research

Latest Cancer News and Research

Vaccine against H. pylori infection is within reach

HOPA Membership Awards winners for 2014 announced at 10th Annual Conference

Novartis to buy Glaxosmithkline's oncology unit

Anxiety experienced with false-positive mammogram does not negatively impact woman's well-being

Studies identify 2 genes highly associated with IBD

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Spire Leeds Hospital invests £200,000 in PENTAX Medical’s HD+ endoscopes

New computational tool identifies undiagnosed illnesses and unknown gene mutations

FDA approves Cyramza to treat patients with advanced stomach cancer

IMPAKT breast cancer conference abstracts online

University of Utah software successfully identifies diseases with unknown gene mutations in three separate cases

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Surgery promising for non-metastatic RCC with thrombus

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Multiple lines of targeted therapy extend life for mRCC patients

Intravesical prostatic protrusion predicts post-surgery incontinence

Nocturnal incontinence poses major burden after female bladder reconstruction

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

First Edition: April 22, 2014

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in